ASTHMATICUS

哮喘病

基本信息

批准号：
7607641
负责人：
Christopher Walton Carroll
金额：
$ 0.08万
依托单位：
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-04-01 至 2008-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7607641
关键词：
AR gene Acute Adrenergic Receptor Agonist Alleles Asthma Breathing Child Clinical Computer Retrieval of Information on Scientific Projects Database Data Dose Drug usage Funding Genetic Variation Genotype Grant Hospitals Institution Intensive Care Units Intravenous Length of Stay Numbers Patients Phenotype Rate Research Research Personnel Resources Source Status Asthmaticus United States National Institutes of Health base receptor response

AR gene Acute Adrenergic Receptor Agonist Alleles Asthma Breathing Child Clinical Computer Retrieval of Information on Scientific Projects Database Data Dose Drug usage Funding Genetic Variation Genotype Grant Hospitals Institution Intensive Care Units Intravenous Length of Stay Numbers Patients Phenotype Rate Research Research Personnel Resources Source Status Asthmaticus United States National Institutes of Health base receptor response

展开

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Receptor agonists are the most important group of drugs used in the treatment of asthma. A number of studies have established that genetic variations of the ¿2-adrenergic receptor have important effects in modulating responses to therapy for asthma. We propose to investigate the influence of a patient's ¿2-adrenergic receptor genotype on the clinical response to b2-AR agonist therapy during acute severe asthma exacerbation in children. The overall objective is to assess the influence of a patient's ¿2-adrenergic receptor (b2-AR) genotype on the clinical response to ¿2-AR agonist therapy. Our hypothesis is that children admitted with status asthmaticus who are homozygous for the Gly16 allele of the ¿2-AR gene have a longer Intensive Care Unit (ICU) length of stays than children who are heterozygous at this locus or homozygous for the Arg16 allele when treated with high-dose continuous ¿2-AR agonists (both inhaled and intravenous). Secondary aims are (1) to assess the rate of improvement in MPIS based on genotype and (2) to attempt to correlate asthma phenotype with genotype by comparing demographic data and hospital course.

该副本是使用众多研究子项目之一由NIH/NCRR资助的中心赠款提供的资源。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构是对于中心，这是调查员的机构。受体激动剂是用于治疗哮喘的最重要的药物。许多研究已经确定，2-肾上腺素能受体的遗传变异在调节对哮喘治疗的反应中具有重要影响。我们建议研究患者的2-肾上腺素受体基因型对儿童急性严重哮喘患者期间对B2-AR激动剂治疗的临床反应的影响。总体目的是评估患者的2-肾上腺素受体（B2-AR）基因型对2-AR激动剂治疗的临床反应的影响。我们的假设是，与在此基因座的杂合或杂质的儿童相比，与Arg16等位基因相比，与高剂量连续的arg16等位基因相比，哮喘的状态哮喘的儿童具有更长的重症监护病房（ICU）长度的较长的重症监护病房（ICU）长度，而持续不断地持续了（ICU）。次要目的是（1）基于基因型评估MPI的提高率，以及（2）试图通过比较人口统计数据和医院课程来将哮喘表型与基因型相关联。